Joe W Ramos, President and CEO in The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, shared a post on LinkedIn:
“I am happy to share our latest paper in JBC. This work is focused on better understanding cancer invasion programs – especially in brain cancer. We are mapping key proteins in cancer invasion programs that allow cancer cells to move to other parts of the body. This process (invasion and metastasis) is what causes death from most cancers.
This paper identifies one small of piece of the puzzle which is how a protein (RSK2) turned on by cancer genes (like Ras and EGFR) can then start a program downstream by phosphorylating another protein called ARHGEF12/LARG that changes cell adhesion and movement by activating specifically RhoA.
Before this work, almost nothing was known about how that works. We show here that RSK2 is able to turn on LARG by causing it to locate at the cell membrane edge and bind and activate RhoA. RhoA is well known to change how cells adhere and move. This new bit of knowledge will help provide a more detailed understanding of this process to better target it and to understand how that may affect the tumor. Congrats to co-authors Won Seok Yang, Steven Scahill, Neda Ghanem, Michelle Matter, Annika Fitz, Hannah Röttig.”
Title: Phosphorylation at S1288 of Leukemia Associated RhoGEF (LARG/ARHGEF12) induces plasma membrane localization and promotes binding and activation of RhoA
Authors: Won Seok Yang, Neda Z. Ghanem, Steven D. Scahill, Maisel J. Caliva, Hannah Röttig, Annika Fitz, Michelle L. Matter, Joe W. Ramos
Read the Full Article.
More posts featuring Joe W. Ramos on OncoDaily.